Abstract 302P
Background
DNA repair pathways are implicated both in carcinogenesis and progression of cancer. The genetically determined baseline expression level of DNA repair genes is associated with risk of cervical pre-cancer and cancer. In this study, we aim to evaluate expression level of one such DNA repair gene -Excision Repair Cross- Complementation Group 4 (ERCC4) and its correlation to various clinical and pathological parameters in cervical cancer in North Indian population.
Methods
Expression profiling of ERCC4 in 55 histopathologically confirmed cervical tumor biopsies and 25 control samples (hysterectomy) were done using Real time PCR(q-PCR), western blot analysis. Correlation analysis was done with different clinical and pathological parameters. ROC curve assessment was done to check the diagnostic utilities of the calculated data. One way ANOVA and t-test were used to calculate statistical significance using Graphpad PRISM 9.
Results
Relative fold change for mRNA expression analysis showed up-regulation of ERCC4 in 78.2% (n=43) patient biopsies, calculated by ΔΔct method. At translational level, the up regulation was around 52% (n=28). The up-regulations were significant with p value less than 0.05. Also, ERCC4, mRNA expression showed positive correlation with tumor stage and grade. Positive correlation was also observed in ERCC4 protein expression with respect to different age groups and histological status. High risk HPV-18 strain type was shown to be more influential in up regulating ERCC4 expression, both at transcriptional and translational level.
Conclusions
ERCC4 is significantly up-regulated at both transcriptional and translational levels in cervical cancer patient cohort, comprising of North Indian population. Higher expression of ERCC4 in tumor samples suggests its role as a potential diagnostic and/or prognostic marker in Ca Cervix.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institute of Medical Sciences, BHU, Varanasi, India.
Funding
BHU under Institute of Eminence (IoE).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract